Rakuten Investment Management Inc. Has $7.36 Million Position in Becton, Dickinson and Company $BDX

Rakuten Investment Management Inc. lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 95.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,706 shares of the medical instruments supplier’s stock after selling 779,363 shares during the period. Rakuten Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $7,359,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Becton, Dickinson and Company by 0.5% during the third quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after purchasing an additional 147,041 shares during the period. Skba Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 1,619.9% during the third quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock worth $10,765,000 after purchasing an additional 54,170 shares during the period. Graybill Wealth Management LTD. grew its stake in shares of Becton, Dickinson and Company by 47.3% during the third quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock worth $5,164,000 after purchasing an additional 8,859 shares during the period. Finally, Danske Bank A S acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth $34,596,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of analyst reports. TD Cowen decreased their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Piper Sandler cut their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. The Goldman Sachs Group cut their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Finally, Argus cut their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $181.00.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total value of $166,628.00. Following the completion of the transaction, the executive vice president owned 14,272 shares of the company’s stock, valued at approximately $2,161,922.56. This trade represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,013 shares of company stock valued at $593,434 over the last ninety days. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.2%

Shares of NYSE:BDX opened at $145.28 on Wednesday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The company’s fifty day simple moving average is $149.64 and its 200 day simple moving average is $173.23. The firm has a market cap of $40.03 billion, a price-to-earnings ratio of 36.78, a PEG ratio of 10.30 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.